Since the use of PPARγ full agonists in the treatment of type-2 diabetes mellitus has been linked to several negative side effects, the development of new alternative candidates as PPARγ ligands has gotten a lot of attention in recent years. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.